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Patellar Tendon Healing
With Platelet-Rich Plasma
A Prospective Randomized Controlled Trial
Adriano Marques de Almeida,*y MD, MS, Marco Kawamura Demange,y MD, PhD,
Marcel Faraco Sobrado,z Marcelo Bordalo Rodrigues,y MD,
Andre´ Pedrinelli,y MD, PhD, and Arnaldo Jose´ Hernandez,y MD, PhD
Investigation performed at the Department of Orthopedics and Traumatology,
Sa˜o Paulo University Medical School, Sa˜o Paulo, Brazil
Background: The patellar tendon has limited ability to heal after harvesting its central third. Platelet-rich plasma (PRP) could
improve patellar tendon healing.
Hypothesis: Adding PRP to the patellar tendon harvest site would improve donor site healing and improve clinical outcome at 6
months after anterior cruciate ligament (ACL) reconstruction with a patellar tendon graft.
Study Design: Randomized controlled trial; Level of evidence, 1.
Methods: Twenty-seven patients were randomly divided to receive (n = 12) or not receive (n = 15) PRP in the patellar tendon
harvest site during ACL reconstruction. The primary outcome was magnetic resonance imaging (MRI) assessment of patellar ten-
don healing (gap area) after 6 months. Secondary outcomes were questionnaires and isokinetic testing of ACL reconstruction with
a patellar tendon graft comparing both groups.
Results: Patellar tendon gap area was significantly smaller in the PRP group (4.9 6 5.3 mm2; 95% confidence interval [CI], 1.1-
8.8) than in the control group (9.46 4.4 mm2; 95% CI, 6.6-12.2; P = .046). Visual analog scale score for pain was lower in the PRP
group immediately postoperatively (3.86 1.0; 95% CI, 3.18-4.49) than in the control group (5.16 1.4; 95% CI, 4.24-5.90; P = .02).
There were no differences after 6 months in questionnaire and isokinetic testing results comparing both groups.
Conclusion: We showed that PRP had a positive effect on patellar tendon harvest site healing on MRI after 6 months and also
reduced pain in the immediate postoperative period. Questionnaire and isokinetic testing results were not different between the
groups at 6 months.
Keywords: platelet-rich plasma; patellar ligament; tendon; growth factors; healing; sports
Platelet-rich plasma (PRP) has been shown experimentally
to improve tendon and ligament healing because of the
presence of an increased concentration of growth factors.38
In rats, PRP injection improved Achilles tendon healing.4
In rabbits, PRP injection increased ultimate strength and
stiffness when applied to the patellar tendon.27
In sports medicine, some studies have shown that PRP
can enhance the recovery of athletes with ligament and ten-
don injuries.15 After anterior cruciate ligament (ACL) recon-
struction, PRP achieved a complete homogeneous graft in
half of the time compared with a control group.31 A level
III study has shown that PRP hastened the recovery of ath-
letes with an Achilles tendon injury.32 Moreover, studies
have shown better outcomes in chronic patellar tendinopathy
with PRP.17,24 The use of PRP in the patellar tendon harvest
site reduced donor site morbidity after ACL reconstruction.9
However, other high-level evidence studies have not
shown benefits in the use of PRP. A level I study found
PRP to be as efficient as saline in Achilles tendinopathy
treatment.16 In ACL reconstructions with allografts, Achil-
les tendon ruptures, and rotator cuff lesions, PRP did not
improve surgical treatment results.8,30,33
Concerning traumatic sports injuries, one might con-
sider the heterogeneity of these lesions, making them
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difficult to compare in prospective randomized trials.14 The
patellar tendon is often used as a graft donor site for ACL
reconstruction. This procedure creates a standard and well-
defined defect, or gap, in the patellar tendon central third.
Several studies assessed harvest site defect healing with
magnetic resonance imaging (MRI), showing that this heal-
ing is usually partial, even after many years.7,21-23,29
In animal studies, patellar tendon defects have been
used as an experimental model to assess the effect of
growth factors and PRP. Basic fibroblast growth factor
used in a patellar tendon defect increased fibroblast prolif-
eration and collagen type III synthesis in rats.10,11 Applica-
tion of transforming growth factor-b1 increased the
mechanical properties of the regenerated tissue in the rab-
bit’s patellar tendon after resection of the central portion.3
Also, PRP improved the mechanical properties of the rab-
bit’s patellar tendon after resection of its central portion.27
In this study, we used the patellar tendon harvest site as
an experimental model to assess the effect of PRP on patel-
lar tendon healing in humans in a prospective, randomized,
evaluator-blinded study. The hypothesis was that adding
PRP to the patellar tendon harvest site would improve ten-
don healing and improve clinical outcome at 6 months after
ACL reconstruction with a patellar tendon graft.
MATERIALS AND METHODS
Approval by the local ethics committee and written
informed consent were obtained. Recruitment started in
November 2008 and was completed in February 2010.
Inclusion criteria were ACL injury, bone maturity, and
age less than 45 years. Exclusion criteria were complex lig-
ament lesions, osteoarthritis, previous surgeries in the
same joint, postoperative infection, arthrofibrosis, reopera-
tion, inadequate follow-up, and thrombocytopenia.
Twenty-eight patients met the inclusion criteria; one
refused to participate. Twenty-seven patients were random-
ized using a computer-generated sequence into 2 groups:
PRP (n = 12) and control (n = 15). The resulting demograph-
ics are summarized in Table 1. In the PRP group of patients,
PRP was added to the patellar tendon defect after harvest-
ing its central third for an ACL reconstruction graft; in the
control group of patients, nothing was added. All patients
received the allocated treatment (Figure 1).
Outcomes
The primary outcome was magnetic resonance imaging
(MRI) assessment of patellar tendon harvest site healing.
On MRI, we also evaluated tendon thickness and length.
Secondary outcomes were functional and clinical evalua-
tions of ACL reconstruction with a patellar tendon graft
to examine whether adding PRP to the harvest site affects
the clinical and functional outcomes of the procedure. We
determined postoperative pain, specific questionnaires of
knee function, and isokinetic testing. Any complication
was reported whether related to the procedures or not.
Our hypotheses were that PRP would increase patellar
tendon defect healing and improve clinical outcome at 6
months after the surgery.
PRP Gel Preparation
Platelet-rich plasma was obtained from each patient from
the PRP group during anesthesia. A Haemonetics MCS1
9000 cell separator with a specific kit for platelet apheresis
995-E (Haemonetics Corp, Braintree, Massachusetts) was
used in the operating room simultaneously with ACL
reconstruction. This cell separator withdraws 450 mL of
autologous whole blood through a peripheral venous cath-
eter. Citrate (10%) was used as anticoagulant. Platelet-rich
TABLE 1
Descriptions of the 2 Groups
Platelet-Rich Plasma Control P Value
No. of patients 12 15 —
Mean age (range), y 25.8 (18-44) 23.1 (15-34) .309b
Men/women, n 10/2 14/1 .569c
Associated lesions,a n 7 9 ..99c
aPatients with meniscal or chondral lesions (grade IV) associ-
ated with anterior cruciate ligament injury.
bStudent t test.
cFisher exact test.
Assessed for eligibility (n=28)
Declined to participate (n=1)
Randomized
(n=27)
PRP group (n=12)
Received intervention 
(n=12)
Control group(n=15)
Received intervention 
(n=15)
VAS pain score (n=12)
Lost to follow-up (n=0)
Answered VAS score (n=12)
VAS pain score (n=15)
Lost to follow-up (n=1)
Answered VAS score (n=14)
Immediate
postop
MRI examination (n=12)
Lost to follow-up (n=2)
Performed MRI (n=10)
MRI examination (n=15)
Lost to follow-up (n=3)
Performed MRI (n=12)
6 months
postop
Postop questionnaires (n=12)
Lost to follow-up (n=2)
Answered questionnaires (n=10)
Postop questionnaires  (n=15)
Lost to follow-up (n=0)
Answered questionnaires (n=15)
Isokinetic testing (n=12)
Lost to follow-up (n=1)
Performed isokinetic testing
Isokinetic testing (n=15)
Lost to follow-up (n=1)
Performed isokinetic testing
(n=11) (n=14)
Figure 1. CONSORT flow diagram.
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plasma was separated from platelet-poor plasma (PPP) and
red blood cells in different sterile collection bags. The red
blood cells and PPP (up to 400 mL) were returned to the
patient from their collection bags through the peripheral
venous access. With this system, we could obtain 30 to
50 mL of PRP. So, in fact, the total amount of blood col-
lected from the patient is up to 50 mL.
The PRP obtained was divided into 10-mL tubes. To the
first tube, 0.8 mL of calcium chloride (CaCl2) was added to
allow clot formation and separate it from the plasma,
which contains autologous thrombin. We added 1 mL of
the resulting plasma with thrombin plus 0.8 mL of CaCl2
to another tube to generate the PRP gel. The average con-
centration of platelets in PRP was 1,185,166/mm3 6
404,472/mm3 and represented an average increase of 7.65
times (range, 3.82-26.03) related to basal levels. Average
white blood cell concentration was 0.91/mm3 6 0.81/mm3.
Surgical Technique
A single surgeon performed all surgical procedures. Under
tourniquet control, a longitudinal incision was made in the
anterior aspect of the knee. The peritendon was open lon-
gitudinally and separated from the underlying patellar
tendon. We obtained a bone–patellar tendon–bone graft
with 1-cm width, measured with a ruler. The ACL recon-
struction was performed arthroscopically using the trans-
tibial drilling technique, and the graft was fixed with
a transverse double pin absorbable system (Rigidfix,
Depuy Orthopaedics, Warsaw, Indiana) in the femur and
an absorbable interference screw in the tibia.
The harvest site was prepared in both groups with
absorbable 3-0 sutures at the patellar tendon margins to
the underlying fat pad to avoid the gel entering the knee
joint through the fat pad (Figure 2). In the PRP group,
the patellar tendon defect was completely filled with 20
to 40 mL of PRP gel (Figure 3), and in the control group,
nothing was added. The peritendon was closed with
absorbable 3-0 sutures without closing the tendon itself.
Postoperative Period and Visual Analog Scale
Suction drains were used inside the knee joint and
removed before the patient was discharged, 24 hours after
the operation. No drains were used in the subcutaneous
tissue. During this period, postoperative analgesia was
carefully monitored, and all patients received the same
medications (ketoprofen, tramadol, sodium dipyrone)
with the same dosage at the same intervals. A visual ana-
log scale (VAS) was used to evaluate pain level at the first
postoperative day. We allowed early range of motion and
progressive weightbearing with crutches for 3 weeks. All
patients followed the same rehabilitation protocol.
Magnetic Resonance Imaging
Patients were requested to have an MRI examination after
6 months to assess patellar tendon harvest site healing. All
MRI studies were performed with a 1.5-T magnetic reso-
nance system (Signa Excite HDXT, GE Healthcare, Wauke-
sha, Wisconsin) by using a dedicated 8-channel knee coil. In
all patients, axial T2-weighted fat-saturated fast spin-echo
sequences (repetition time [TR]/echo time [TE], 3500-4467/
65-70 milliseconds; echo train length, 8; 32 sections; number
of signals acquired, 3; acquisition time, 4:35 minutes; band-
width, 31.25 kHz) and sagittal T2-weighted fat-saturated
(TR/TE, 3600-4100/84-88; echo train length, 10; 23 sections;
number of signals acquired, 2; acquisition time, 3:50
minutes; bandwidth, 31.25 kHz) and intermediate-weighted
(TR/TE, 2000-2300/14-18; echo train length, 6; 23 sections;
number of signals acquired, 2; acquisition time, 3:10
minutes; bandwidth, 41.67 kHz) fast spin-echo sequences
were performed. Sequence parameters included 3.5-mm sec-
tion thickness, 256 to 512 3 192 to 256 matrix size, and 140
3 140-mm field of view. An independent, experienced mus-
culoskeletal radiologist performed all blinded evaluations.
Using the MRI reconstruction program and computer-
ized distance measurements, the following parameters
Figure 2. Patellar tendon harvest site prepared to receive (or
not) platelet-rich plasma.
Figure 3. Platelet-rich plasma gel being added to the patel-
lar tendon harvest site.
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were considered based on previously published data
(Figure 4).7,21-23,29
1. Gap area of the patellar tendon harvest site (mm2):
in the axial direction, the gap size was evaluated in
the donor site corresponding to non–tendinous-like
tissue signal. Measurement was performed at the
midpoint through the length of the tendon from the
apex of the patella to the insertion at the tibial
tubercle.
2. Cross-sectional area of the patellar tendon (mm2): in
the axial direction, at the same point, the cross-
sectional area of the entire ligament, including the
defect, was determined to assess ligament thickness.
3. Patellar height was assessed in the sagittal view
with the Insall-Salvati index, determined by the
patella length and patellar tendon length ratio.
Isokinetic Testing and Questionnaires
Before the surgical procedure, patients answered knee
function questionnaires (Lysholm, subjective International
Knee Documentation Committee, Kujala, and Tegner) and
submitted to isokinetic testing. These procedures were
repeated 6 months after surgery. Isokinetic strength meas-
urements of the quadriceps and hamstring muscles were
performed on a Biodex System 3 Pro (Biodex Medical Sys-
tems Inc, Shirley, New York) at 60 and 240 deg/s. We com-
pared the quadriceps peak torques of the injured and
noninjured leg to calculate the quadriceps peak torque
deficit.
Statistical Analysis
Magnetic resonance imaging data, patient age, and VAS
score were analyzed with the Student t test. For VAS score,
patient age was controlled with analysis of variance
(ANOVA). Statistical analysis of associated chondral or
meniscal lesions and patient gender were performed using
the Fisher exact test. Questionnaire and isokinetic testing
data were compared with the Student t test or the Mann-
Whitney U test, depending on distribution. All P values
were 2-sided. A P value of .05 indicated a statistically sig-
nificant difference.
RESULTS
No adverse effects occurred in these patients. Detailed
descriptions of the demographics of the 2 groups are shown
in Table 1. No differences were found between groups
related to age, gender, or meniscal and chondral lesions
related to ACL injury.
Magnetic Resonance Imaging
Magnetic resonance imaging was performed after surgery
at an average of 208 days in PRP group patients and 212
days in control group patients, with no statistical differ-
ence. Patellar tendon harvest site nonregenerated area
(gap area) in the PRP group patients was 4.9 6 5.4 mm2
(95% confidence interval [CI], 1.1-8.8) and in the control
group patients was 9.4 6 4.4 mm2 (95% CI, 6.6-12.2). Sta-
tistical analysis showed a significant difference between
groups (P = .046). There were no differences between the
groups in the cross-sectional area of the patellar tendon
or patella height, as reported in Table 2.
VAS Score
Postoperative average VAS pain score in the PRP patients
was 3.8 6 1.0 (95% CI, 3.18-4.49) compared with 5.1 6 1.4
(95% CI, 4.24-5.90) in the control group. The difference was
Figure 4. Using magnetic resonance imaging (MRI), (A) the gap area of the patellar tendon harvest site and the cross-sectional
area of the patellar tendon (B) were calculated through the midpoint along the length of the tendon from the apex of the patella to
the insertion at the tibial tubercle, as shown in this control group patient. (C) An MRI scan of a platelet-rich plasma group patient,
showing a smaller gap (arrow).
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statistically significant, indicating that PRP patients had
less postoperative pain (P = .02).
Questionnaires and Isokinetic Testing
Comparing preoperative and postoperative results on sub-
jective tests, we found that 6 months after arthroscopic
ACL reconstruction surgery, both groups improved all
scores except for the Tegner. On the Tegner questionnaire,
both groups had worse results. When comparing the ques-
tionnaire scores of the 2 groups, there was no statistically
significant difference. Comparing preoperative and postop-
erative quadriceps isokinetic testing results, both groups
had an increased quadriceps peak torque deficit 6 months
after ACL reconstruction. There was no statistically signif-
icant difference in quadriceps peak torque deficit between
groups (Table 3).
DISCUSSION
Harvesting the patellar tendon surgically creates a stan-
dardized defect, or gap, in the tendon central third. We
used it as an experimental model to assess the effect of
PRP on patellar tendon healing.
Platelet-rich plasma has been used to improve the
recovery of ligament and tendon injuries in athletes, in
spite of a lack of definite clinical evidence.12,18,26 Previous
experimental data have shown an improvement in patellar
tendon healing in rabbits with PRP, with increased force at
failure, ultimate stress and stiffness, and collagen synthe-
sis.27 Application of PRP gel at the patellar tendon donor
site level significantly reduced knee pain after ACL recon-
struction with patellar tendon grafts.9 In that study, the
authors showed no difference in the MRI signal of the ten-
don donor site compared with a control group, but their
evaluation was only qualitative and not quantitative.
Previous studies have used MRI to evaluate quantita-
tively the natural outcome of the patellar tendon after har-
vesting its central third, showing a progressive gap
reduction, with a plateau after 2 years,7,21-23 and a persis-
tent defect even after many years.28,34,35 Previous histo-
chemical and ultrastructural study of the patellar tendon
donor site showed that it does not normalize over
time.6,25,35
We showed that the patellar tendon had a significantly
smaller gap size in the PRP group than in the control cases
TABLE 2
Magnetic Resonance Imaging (MRI) Measurements
Platelet-Rich Plasma Control P Valuea
Days to perform MRI, mean (range) 208 (170-266) 212 (170-285) .83
Gap area, mean 6 SD, mm2 4.9 6 5.4 9.4 6 4.4 .046b
Cross-sectional area, mean 6 SD, mm2 173.0 6 30.5 176.3 6 48.6 .856
Insall-Salvati index, mean 6 SD 1.0 6 0.1 1.1 6 0.2 .806
aStudent t test.
bStatistically significant (P\ .05).
TABLE 3
Preoperative and Postoperative Results of Isokinetic Testing and Questionnairesa
PRP Control PRP 3 Controlc
Preoperative Final Pb Preoperative Final Pb Preoperative Final
Peak torque deficit
at 60 deg/sd
27.3 6 34.4 44.7 6 18.0 .03 18.2 6 14.2 40.8 6 12.3 \.001 .86 .82
Peak torque deficit
at 240 deg/sd
16.8 6 28.7 30.6 6 21.9 .08 11.4 6 15.8 30.9 6 10.8 \.001 .77 .57
Lysholme 63.5 (45-88) 91.5 (64-100) .001 58.0 (25-75) 89 (69-100) \.001 .2 .56
IKDCe 54.3 (25.3-83.9) 79.3 (50.6-96.6) .02 55.2 (25.3-93.1) 73.5 (52.9-98.9) \.001 .83 .61
Kujalae 62.5 (32-98) 88.5 (70-98) .002 69 (51-91) 86 (72-95) \.001 .81 .33
Tegnere 9 (7-10) 5 (4-7) \.001 7 (5-10) 4 (4-9) \.001 .07 .21
VASe — 4 (2-6) — — 5 (2-7) — — .02f
aPRP, platelet-rich plasma; IKDC, International Knee Documentation Committee; VAS, visual analog scale.
bStudent t test (paired).
cMann-Whitney test, P values.
dPercentage deficit from the noninjured side; mean 6 standard deviation.
eMedian (range).
fStudent t test with ANOVA.
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after 6 months. It indicates that PRP enhanced tendon
healing. To verify the possibility of thickening or shorten-
ing of the patellar tendon, we also evaluated tendon thick-
ness and length and showed no difference between the
groups.
As secondary objectives, we evaluated the clinical and
functional outcomes of ACL reconstruction comparing
both groups. The VAS pain scores were lower in the PRP
group than in the control group in the immediate postoper-
ative period. This analgesic effect of PRP was also shown in
other applications, such as knee arthroplasty19 and peri-
odontal surgery.2 This may be because of the presence of
substances in PRP other than the growth factors, such as
serotonin, dopamine, and catecholamines.12
The exact mechanisms of action of PRP are not fully
understood. Mechanical load is essential to tendon healing.
One experiment in rats37 evaluated the effect of PRP and
botulinum toxin in the Achilles tendon. They found that
the paralyzation of the gastrocnemius muscle with this
toxin reduced the positive effect of PRP in tendon healing.
They concluded that there is an interplay between PRP
action and mechanical load, with PRP-treated tendons
responding earlier to this stimulus. However, many in
vitro studies have shown a positive effect of growth factors
and PRP without mechanical load.1,5,10 Therefore, we
believe that both mechanisms, direct and indirect, are
involved.
After 6 months, knee function scores were improved in
both groups, except the Tegner results, where the findings
worsened in both groups. This is expected because Tegner
questionnaires address sports activities,36 and at 6
months, most patients are beginning to return to strenu-
ous sports after ACL reconstruction.20 Regarding the quad-
riceps isokinetic testing, both groups had an increased
quadriceps peak torque deficit at 6 months compared
with preoperative levels. This was also expected according
to the literature.13 These instruments of evaluation are not
specific for donor site morbidity and determine the results
of ACL rupture treatment, in which harvest site morbidity
is just a part of the outcome.
Strengths of this study are that it is a prospective, ran-
domized, and evaluator-blinded study, in which all param-
eters were evaluated independently. Another strength is
the injury pattern, which creates a standard defect in the
central portion of the patellar tendon. Through this exper-
imental model, we could assess and compare patellar
tendon harvest site healing after a standardized and
well-established procedure.
This study has provided some interesting insights but
also has some limitations. A weakness in this study is
the small number of patients. We had no previously pub-
lished data to estimate the difference between the groups
to calculate the sample size. Second, VAS pain was mea-
sured only within the first 24 hours after the surgery, so
the duration of the difference in pain is unknown. How-
ever, pain is one query of the knee function scores used
in this study, which showed no difference between the
groups after 6 months.
This clinical follow-up period is considered short for
ACL surgery outcomes, but our purpose was not to assess
the final outcomes of ACL reconstruction surgery but to
evaluate whether there was any clinical difference
between the groups. Despite better healing of the patellar
tendon harvest site in PRP group patients, we did not find
any difference in the score results. We also made a power
analysis for these variables and found that, to show a sig-
nificant difference between the groups, the sample size
would need to be huge. We believe that the need for a large
sample size in an ACL surgical study may translate in
a low clinical significance of the intervention. Finally,
a biopsy of the tissue was not performed, and therefore,
we cannot comment on whether the structure, composition,
or mechanical properties of the patellar tendon were
improved by PRP.
In conclusion, we confirmed the hypothesis that PRP
could improve tissue healing at the patellar tendon harvest
site. Platelet-rich plasma also reduced pain in the immediate
postoperative period. With the clinical and functional evalu-
ation instruments used in this study, we were not able to
find any difference in the outcome of the procedure, and
therefore, PRP did not seem to improve patients’ early recov-
ery after ACL reconstruction with a patellar tendon graft.
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